Skip to main content
HR 5657 117th Congress House Health Administrative law and regulatory procedures Alternative treatments Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Drug trafficking and controlled substances Food and Drug Administration (FDA) Health personnel Licensing and registrations Medical research Research administration and funding

Medical Marijuana Research Act

Introduced: October 21, 2021 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 13 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 5, 2022
Received in the Senate.
Apr 4, 2022
Motion to reconsider laid on the table Agreed to without objection.
Apr 4, 2022
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108). (text: CR H4136-4138)
Apr 4, 2022
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 343 - 75 (Roll no. 108).(text: CR H4136-4138)
Apr 4, 2022
Considered as unfinished business. (consideration: CR H4144-4145)
Apr 4, 2022
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Apr 4, 2022
DEBATE - The House proceeded with forty minutes of debate on H.R. 5657.
Apr 4, 2022
Considered under suspension of the rules. (consideration: CR H4136-4140)
Apr 4, 2022
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Oct 22, 2021
Referred to the Subcommittee on Health.
Oct 21, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 21, 2021
Sponsor introductory remarks on measure. (CR E1126)
Oct 21, 2021
Introduced in House
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
Apr 4, 2022 House · vote #108 On Motion to Suspend the Rules and Pass, as Amended Passed 343–75 See who voted →
 Plain-English summary Congressional Research Service

Medical Marijuana Research Act

This bill establishes a new, separate registration process to facilitate medical marijuana research.

Specifically, it directs the Drug Enforcement Administration to register (1) practitioners to conduct medical marijuana research, and (2) manufacturers and distributors to supply marijuana for such research.

Additionally, the Department of Health and Human Services must continue to produce marijuana through the National Institute on Drug Abuse Drug Supply Program and implement a specialized process for supplying marijuana products available through state-authorized marijuana programs to researchers until manufacturers and distributors can provide a sufficient supply of marijuana for medical research.

What's happening now April 5, 2022

Received in the Senate.

 Committees of jurisdiction 4
 Cosponsors 9
All 9 Democratic 5 Republican 4